Entera Bio (ENTX)

The company’s lead program, EB613, is an oral formulation of human parathyroid hormone (PTH 1-34) being developed as an osteoanabolic therapy for osteoporosis. Unlike antiresorptive drugs that primarily slow bone loss, osteoanabolic treatments are intended to stimulate new bone formation, a potentially important option for patients at high fracture risk. Entera is also developing EB612, an oral PTH replacement candidate for hypoparathyroidism, a rare endocrine disorder in which patients have insufficient parathyroid hormone and may require long-term management of calcium and phosphate balance.

Beyond PTH-based candidates, Entera’s pipeline includes oral peptide programs tied to large metabolic and gastrointestinal markets, including an oral GLP-1 candidate for obesity and an oral GLP-2 approach for short bowel syndrome. The company is based in Israel and operates as a development-stage biopharmaceutical business, meaning its value is closely tied to clinical trial progress, regulatory outcomes, intellectual property, and potential partnerships. Its strategy is distinctive because it targets established biologic mechanisms while attempting to improve convenience and adherence through tablet-based delivery.